C2RS34 trade ideas
CRISPR Gene editing. Want your kids to have eagle wings? FUTURETechnical breakdown of CRISPR gene editing with ya boy Meteor Hammer,
First off, This technology really will change the future and these are the pioneers. could potentially end all disease and cure cancer, think about it... Amazing and spooky shit ladies and gentlemen.
This chart looks great. Price just broke through a critical line, and re-entered what could prove to be a falling wedge continuation pattern. watch for the breakout so we could head to $60.00 and beyond!
Get money and change the world? shiiiiiiiit.
Love,
SK
Is CRISPR the future or just a cool name? (3)the stock market had a rough time this year but CRSP did not! this company gained 300% when the overall market going sideways. After that massive gain the stock had to pullback and it has lost 38% so far.
Timing = 1 ( I think the market is at the top of its range so more blood could come before this stock bounces real bounce)
Volume = 1 (volume has been weak on the pullback which is good sign for bulls)
Group strength = 0 (biotech looks to be doing ok on the index)
Entry = 1 (alot of strong technical support in this area fibonacci + the 200ma + the recently completed ABCD pattern)
Fractal = 0 (a previous pullback was 45% so that might indicate there could be more downside)
CRSPR price actionThe uprise is overheated an is loosing momentum. One more push to the upside (a wave b of the present abc correction) will complete the "three pushes " series, in which the upthrust above the upper Keltner channel border decreases continuously. Afterwards, a fall to the lowest trendline is possible. After that, a sharp ascent to the highest trendline is likely.
$CRSP Crispr Therapeutics - Hammer Time$CRSP Crispr Therapeutics - big hammer candlestick today holding the lower limit of a bullish channel which began in January. Expecting continuation bounce in the very near term. See chart for two possible medium term targets by next earnings release in August.
Stop loss - $56.00
Note - Observation/opinion, not investment advice.
CRSP price actionThe strong uptrend may enter its last phase. Upthrusts above the upper Keltner line gets less pronounced, ascents (red) less steep. There are smaller ascents and deeper corrections. A third push may be expected to the upper trend channel line to about 80 USD, but afterwards the price could be expected to fall to the lower channel line, perhaps to around 40 USD.
CRSP - Market Overreaction, looking for long entryCRSPR is possibly one of the most important medical discoveries of this century.
Media reports of that it "might" cause cancer are clearly overblown as any scientist in the industry will tell you.
Do your own due diligence there, this is clearly an overreaction.
Fried foods might cause cancer too, doesnt seem to hurt YUM that much
Will be looking for entry around the 200SMA in this and in NTLA and SGMO, two other companies doing CRSPR R&D.
CRSPR extremely strongVery strong price action. The middle line of the Keltner channel (EMA 20) is not reached during the uptrend, The breakout level of the last correction was just so retraced, but no stops below could be triggered. wave 3 started with a lot of upside potential. Bars may go along the upper channel line for a substantial period of time.
Target may be around 158 $ if wave 3 is 2,61 x wave 1.
CRSP Bullish Pennet BREAK OUTLadies and gents.
Overview this chart and everything I post. I have been trading the markets for 4 years straight with out missing more than 20 or 30 days in that whole time period. This chart shows a perfect example of how bullish patterns occurs and how they are bought. The most important lesson of this picture is to make sure you are a dip buyer and not the break out buyer. Beginner traders buy the break out, but pros buy the dips and sell the break out to the beginner traders!
CRSP Continues to Climb and Impress - Bullish Was looking at this back in January at ~ $27/share, mentioned it again at $50/share, now might be the last big time to get in on the climb. Shoot your shots boys. NASDAQ:CRSP
Option Sale OpportunityCRSP is admittedly a VERY volatile name, but one with a big future and I believe a CL list stock at GS.
On Friday, I was able to sell the May $45 puts for $1.90.
If I am exercised, my cost basis will be $43.10, which puts it right in the support of the bottom of the last pullback.
I would be OK getting exercised on that and I could exit for a small loss if it violated the low of that prior pullback.
If I don't get exercised, I've earned roughly 4% of the strike price for 4 weeks exposure for a strike that is roughly 20% OTM.
I can live with that, too, as one will come close to making my monthly car payment.
Drawback: There is obviously an earnings report between now and expiration.
Add your thoughts
Investing In Genomics Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR.
Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com
NASDAQ:CRSP
Many Thanks.
R.M.D
Investing In GenomicsAnyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR.
Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com
NASDAQ:CRSP
Many Thanks.
R.M.D
Bullish starting from low $32's / 33's. I like CRSP but watchingReally like CRSP, I like what it's about, but it's still speculative. I'll be a buyer if price lowers by 25%
CRSP Continues To Climb - BullishThis chart looked good in January when the market was on fire, and it still continues to look good despite hiccups along the way! Bullish.
CRSP In For A Positive YearCRSP Gains, gains, more gains. Looking good so far this year. Gene editing seeking to cure diseases and cancer. Don't sleep on this one. Hitting some all time highs right now so wait for a moment to get down to the $22's and $21's and watch for a good return in the future.
